公共部门取代私人资助的制药研发:成本和效率考虑
David Proudman1, Urvi Desai1, Dumingu Aparna Gomes1
1Analysis Group, Inc, Boston, MA, USA.
Journal of medical economics
|October 3, 2024
概括
用公共资金取代私人制药研发资金,每年将花费1396亿美元. 纳税人资助的大幅增加是维持目前制药创新率所必需的.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 创新研究 研究 创新研究
背景情况:
- 对基础医学研究的公共资金产生长期效益.
- 目前正在讨论如何用公共资金取代私人制药研发 (R&D) 资金.
- 保持目前制药创新的速度是一个关键考虑因素.
研究的目的:
- 研究用公共资金取代私人研发资金的经济影响.
- 通过公共资金来估计与维持目前制药创新步伐相关的成本.
- 评估公共资金替代的潜在挑战和效率.
主要方法:
- 估计每种已批准药物的生命周期总研发成本,使用研发支出,批准可能性和财务账户.
- 根据FDA的年度批准分层化研发成本,以估计私营部门的研发融资成本.
- 进行文献审查,以评估经济效率和公共资金替代的潜在挑战.
主要成果:
- 总生命周期研发成本估计为每种已批准的药物283亿美元.
- 取代一年的私人研发资金用于FDA批准,估计将花费1396亿美元.
- 公共资金替代几乎没有改善经济效率的证据,并提出了信息不对称和寻找租金等挑战.
结论:
- 私营部门承担了大部分药品研发投资.
- 公共话语可能低估了私人风险资本在药物开发中的关键作用.
- 取代私人投资以维持创新产出将需要大幅增加纳税人的资金.
关键词:
在这里,我们可以看到C C C C CC5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5 C5在C54 的情况下,C54这就是为什么我会这样做.E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E6 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7 E7E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61 E61在这里,我们可以看到H H H H H H.H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H5 H3 H5 H5 H5 H5 H3 H5 H5 H3 H4 H5 H5 H5 H5 H3 H5 H3 H4 H5 H6 H7 H8 H8 H8 H8 H9 在线阅读更多H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51 H51我已经开始了,我已经开始了.第111章 这是什么?美国国家卫生研究院 (NIH)制药研发领域的研发工作.研发政策的研究和发展政策.互补性 互补性 互补性制药政策 制药政策公共的研发工作.相关概念视频
Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Drug Control Governance: Regulatory Bodies and Their Impact
706
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
706
Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Biopharmaceutical Factors Influencing Drug Product Design: Overview
547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259


